Somatic and reproductive development in pre-pubertal mice treated with cyclophosphamide and subsequent estrogen replacement

Rebecca A. Uhlmann, Cherichi Ogwo, Robert Williams, Shelby E. Osborne, Lucy J. Williams, Laura Detti

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We tested the hypothesis that chemotherapy would prevent the expected pubertal development of uterus, ovaries, and long bones, and that estrogen replacement subsequent to treatment with chemotherapy would restore uterine and bone development to expected sizes. Pre-pubertal female C57BL/6J mice (n = 78) were assigned to receive placebo (controls), 200 mg/kg (group A), or 120 mg/kg (group B) of cyclophosphamide (CTX) on postnatal day 18. Mice were subsequently randomized to receive estradiol placebo or long-release estradiol pellet insertion on day 22 (early estradiol dose), day 45 (mid estradiol dose), or day 67 (late estradiol dose) of life. Body weight and length, uterine and ovarian weight, and right femur length and weight were measured. Mice treated with CTX had shorter and lighter femurs and lighter ovaries than controls (13.46 cm ± 1.51 cm vs. 15.00 cm ± 1.10 cm, 57.70 mg ± 9.71 mg vs. 65.30 mg ± 3.68 mg, and 5.16 mg ± 3.00 mg vs. 10.05 mg ± 2.31 mg, respectively; p < 0.05). Mice receiving estrogen replacement had a larger average body weight, BMI, and uterine weight than those that received placebo estrogen (19.56 g ± 1.82 g vs. 18.10 g ± 2.08 g, 26.53 g/cm2 ± 2.91 g/cm2 vs. 23.47 g/cm2 ± 3.06 g/cm2, 101.19 mg ± 41.69 mg vs. 50.00 mg ± 9.49 mg, respectively; p < 0.05). Cyclophosphamide treatment in pre-pubertal mice negatively affected femur and reproductive development. Estrogen treatment restored expected uterine development by maturity, regardless of the timing of administration. However, there was no similar recovery of femur length and bone mass was only partially recovered.

Original languageEnglish (US)
Pages (from-to)337-341
Number of pages5
JournalSystems Biology in Reproductive Medicine
Volume59
Issue number6
DOIs
StatePublished - Dec 1 2013

Fingerprint

Estrogen Replacement Therapy
Cyclophosphamide
Estradiol
Femur
Placebos
Weights and Measures
Ovary
Estrogens
Body Weight
Bone and Bones
Drug Therapy
Bone Development
Inbred C57BL Mouse
Uterus
Therapeutics

All Science Journal Classification (ASJC) codes

  • Reproductive Medicine
  • Urology

Cite this

Somatic and reproductive development in pre-pubertal mice treated with cyclophosphamide and subsequent estrogen replacement. / Uhlmann, Rebecca A.; Ogwo, Cherichi; Williams, Robert; Osborne, Shelby E.; Williams, Lucy J.; Detti, Laura.

In: Systems Biology in Reproductive Medicine, Vol. 59, No. 6, 01.12.2013, p. 337-341.

Research output: Contribution to journalArticle

@article{b147bf282fea4c9ba83bb6f02ae80e18,
title = "Somatic and reproductive development in pre-pubertal mice treated with cyclophosphamide and subsequent estrogen replacement",
abstract = "We tested the hypothesis that chemotherapy would prevent the expected pubertal development of uterus, ovaries, and long bones, and that estrogen replacement subsequent to treatment with chemotherapy would restore uterine and bone development to expected sizes. Pre-pubertal female C57BL/6J mice (n = 78) were assigned to receive placebo (controls), 200 mg/kg (group A), or 120 mg/kg (group B) of cyclophosphamide (CTX) on postnatal day 18. Mice were subsequently randomized to receive estradiol placebo or long-release estradiol pellet insertion on day 22 (early estradiol dose), day 45 (mid estradiol dose), or day 67 (late estradiol dose) of life. Body weight and length, uterine and ovarian weight, and right femur length and weight were measured. Mice treated with CTX had shorter and lighter femurs and lighter ovaries than controls (13.46 cm ± 1.51 cm vs. 15.00 cm ± 1.10 cm, 57.70 mg ± 9.71 mg vs. 65.30 mg ± 3.68 mg, and 5.16 mg ± 3.00 mg vs. 10.05 mg ± 2.31 mg, respectively; p < 0.05). Mice receiving estrogen replacement had a larger average body weight, BMI, and uterine weight than those that received placebo estrogen (19.56 g ± 1.82 g vs. 18.10 g ± 2.08 g, 26.53 g/cm2 ± 2.91 g/cm2 vs. 23.47 g/cm2 ± 3.06 g/cm2, 101.19 mg ± 41.69 mg vs. 50.00 mg ± 9.49 mg, respectively; p < 0.05). Cyclophosphamide treatment in pre-pubertal mice negatively affected femur and reproductive development. Estrogen treatment restored expected uterine development by maturity, regardless of the timing of administration. However, there was no similar recovery of femur length and bone mass was only partially recovered.",
author = "Uhlmann, {Rebecca A.} and Cherichi Ogwo and Robert Williams and Osborne, {Shelby E.} and Williams, {Lucy J.} and Laura Detti",
year = "2013",
month = "12",
day = "1",
doi = "10.3109/19396368.2013.828110",
language = "English (US)",
volume = "59",
pages = "337--341",
journal = "Systems Biology in Reproductive Medicine",
issn = "1939-6368",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Somatic and reproductive development in pre-pubertal mice treated with cyclophosphamide and subsequent estrogen replacement

AU - Uhlmann, Rebecca A.

AU - Ogwo, Cherichi

AU - Williams, Robert

AU - Osborne, Shelby E.

AU - Williams, Lucy J.

AU - Detti, Laura

PY - 2013/12/1

Y1 - 2013/12/1

N2 - We tested the hypothesis that chemotherapy would prevent the expected pubertal development of uterus, ovaries, and long bones, and that estrogen replacement subsequent to treatment with chemotherapy would restore uterine and bone development to expected sizes. Pre-pubertal female C57BL/6J mice (n = 78) were assigned to receive placebo (controls), 200 mg/kg (group A), or 120 mg/kg (group B) of cyclophosphamide (CTX) on postnatal day 18. Mice were subsequently randomized to receive estradiol placebo or long-release estradiol pellet insertion on day 22 (early estradiol dose), day 45 (mid estradiol dose), or day 67 (late estradiol dose) of life. Body weight and length, uterine and ovarian weight, and right femur length and weight were measured. Mice treated with CTX had shorter and lighter femurs and lighter ovaries than controls (13.46 cm ± 1.51 cm vs. 15.00 cm ± 1.10 cm, 57.70 mg ± 9.71 mg vs. 65.30 mg ± 3.68 mg, and 5.16 mg ± 3.00 mg vs. 10.05 mg ± 2.31 mg, respectively; p < 0.05). Mice receiving estrogen replacement had a larger average body weight, BMI, and uterine weight than those that received placebo estrogen (19.56 g ± 1.82 g vs. 18.10 g ± 2.08 g, 26.53 g/cm2 ± 2.91 g/cm2 vs. 23.47 g/cm2 ± 3.06 g/cm2, 101.19 mg ± 41.69 mg vs. 50.00 mg ± 9.49 mg, respectively; p < 0.05). Cyclophosphamide treatment in pre-pubertal mice negatively affected femur and reproductive development. Estrogen treatment restored expected uterine development by maturity, regardless of the timing of administration. However, there was no similar recovery of femur length and bone mass was only partially recovered.

AB - We tested the hypothesis that chemotherapy would prevent the expected pubertal development of uterus, ovaries, and long bones, and that estrogen replacement subsequent to treatment with chemotherapy would restore uterine and bone development to expected sizes. Pre-pubertal female C57BL/6J mice (n = 78) were assigned to receive placebo (controls), 200 mg/kg (group A), or 120 mg/kg (group B) of cyclophosphamide (CTX) on postnatal day 18. Mice were subsequently randomized to receive estradiol placebo or long-release estradiol pellet insertion on day 22 (early estradiol dose), day 45 (mid estradiol dose), or day 67 (late estradiol dose) of life. Body weight and length, uterine and ovarian weight, and right femur length and weight were measured. Mice treated with CTX had shorter and lighter femurs and lighter ovaries than controls (13.46 cm ± 1.51 cm vs. 15.00 cm ± 1.10 cm, 57.70 mg ± 9.71 mg vs. 65.30 mg ± 3.68 mg, and 5.16 mg ± 3.00 mg vs. 10.05 mg ± 2.31 mg, respectively; p < 0.05). Mice receiving estrogen replacement had a larger average body weight, BMI, and uterine weight than those that received placebo estrogen (19.56 g ± 1.82 g vs. 18.10 g ± 2.08 g, 26.53 g/cm2 ± 2.91 g/cm2 vs. 23.47 g/cm2 ± 3.06 g/cm2, 101.19 mg ± 41.69 mg vs. 50.00 mg ± 9.49 mg, respectively; p < 0.05). Cyclophosphamide treatment in pre-pubertal mice negatively affected femur and reproductive development. Estrogen treatment restored expected uterine development by maturity, regardless of the timing of administration. However, there was no similar recovery of femur length and bone mass was only partially recovered.

UR - http://www.scopus.com/inward/record.url?scp=84894205996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894205996&partnerID=8YFLogxK

U2 - 10.3109/19396368.2013.828110

DO - 10.3109/19396368.2013.828110

M3 - Article

VL - 59

SP - 337

EP - 341

JO - Systems Biology in Reproductive Medicine

JF - Systems Biology in Reproductive Medicine

SN - 1939-6368

IS - 6

ER -